Femasys (FEMY)
Market Price (8/24/2026): $2.89 | Market Cap: $9.7 MilSector: Health Care | Industry: Health Care Equipment
Femasys (FEMY)
Market Price (8/24/2026): $2.89Market Cap: $9.7 MilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -63% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -137% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -764% Weak revenue growthRev Chg QQuarterly Revenue Change % is -19% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 26% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -768%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -791% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -123% High stock price volatilityVol 12M is 137% Key risksFEMY key risks include [1] a precarious financial position creating substantial risk of shareholder dilution, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -63% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -125%, 3Y Excs Rtn is -137% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -764% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -19% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 26% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -768%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -791% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -123% |
| High stock price volatilityVol 12M is 137% |
| Key risksFEMY key risks include [1] a precarious financial position creating substantial risk of shareholder dilution, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Femasys (FEMY) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Continued Lack of Substantial Revenue and Weak Q2 2026 Financial Performance.
Femasys reported a net income of $846,100 in fiscal Q1 2026 (ended March 31, 2026), but some reports highlighted no revenue for the quarter, and the stock declined 14.57% following this announcement. This trend continued into fiscal Q2 2026 (ended June 30, 2026), where the company significantly missed analyst expectations, reporting a net loss of $4,469,095, or ($1.33) per diluted share, against an estimated loss of ($1.13) per share. Quarterly revenue for Q2 2026 was $331,827, falling considerably short of the consensus estimate of $1.16 million and representing a decline from $409,268 in Q2 2025. The consistent underperformance in revenue generation and wider-than-expected losses contributed to investor disappointment.
2. Implementation of a Reverse Stock Split.
Femasys executed a 1-for-20 reverse stock split in early June 2026. While this action allowed the company to regain compliance with Nasdaq listing requirements by June 24, 2026, reverse stock splits are often viewed as a negative indicator by investors, signaling underlying financial difficulties or a struggle to maintain a viable stock price, leading to further downward pressure on the share value.
Show more
Femasys (FEMY) stock has lost about 60% since 4/30/2026 because of the following key factors:
1. Continued Lack of Substantial Revenue and Weak Q2 2026 Financial Performance.
Femasys reported a net income of $846,100 in fiscal Q1 2026 (ended March 31, 2026), but some reports highlighted no revenue for the quarter, and the stock declined 14.57% following this announcement. This trend continued into fiscal Q2 2026 (ended June 30, 2026), where the company significantly missed analyst expectations, reporting a net loss of $4,469,095, or ($1.33) per diluted share, against an estimated loss of ($1.13) per share. Quarterly revenue for Q2 2026 was $331,827, falling considerably short of the consensus estimate of $1.16 million and representing a decline from $409,268 in Q2 2025. The consistent underperformance in revenue generation and wider-than-expected losses contributed to investor disappointment.
2. Implementation of a Reverse Stock Split.
Femasys executed a 1-for-20 reverse stock split in early June 2026. While this action allowed the company to regain compliance with Nasdaq listing requirements by June 24, 2026, reverse stock splits are often viewed as a negative indicator by investors, signaling underlying financial difficulties or a struggle to maintain a viable stock price, leading to further downward pressure on the share value.
3. Significant Analyst Price Target Reductions.
In August 2026, prominent investment firms drastically cut their price targets for Femasys. Lake Street lowered its price target from $30 to $10 per share on August 18, 2026, and Maxim Group also reduced its target from $30 to $10 per share on August 14, 2026. These substantial downgrades by analysts reflect a diminished outlook for the company's future prospects and valuation, contributing to the stock's decline.
4. Share Dilution from Private Placement.
Femasys completed a $30 million private placement in August 2026, with the potential for an additional $60 million from warrant exercises. While this financing is intended to support the commercialization of its FemaSeed product and the FemBloc clinical program, the issuance of new shares and associated warrants often leads to dilution for existing shareholders, which can exert downward pressure on the stock price.
Show less
Stock Movement Drivers
Fundamental Drivers
The -59.5% change in FEMY stock from 4/30/2026 to 8/23/2026 was primarily driven by a -54.5% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.30 | 2.96 | -59.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 0.3% |
| P/S Multiple | 9.5 | 4.3 | -54.5% |
| Shares Outstanding (Mil) | 3 | 3 | -11.2% |
| Cumulative Contribution | -59.5% |
Market Drivers
4/30/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| FEMY | -59.5% | |
| Market (SPY) | 6.5% | 24.4% |
| Sector (XLV) | 19.6% | 4.3% |
Fundamental Drivers
The -72.3% change in FEMY stock from 1/31/2026 to 8/23/2026 was primarily driven by a -59.4% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.70 | 2.96 | -72.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 11.5% |
| P/S Multiple | 10.6 | 4.3 | -59.4% |
| Shares Outstanding (Mil) | 2 | 3 | -38.9% |
| Cumulative Contribution | -72.3% |
Market Drivers
1/31/2026 to 8/23/2026| Return | Correlation | |
|---|---|---|
| FEMY | -72.3% | |
| Market (SPY) | 11.0% | 27.5% |
| Sector (XLV) | 13.3% | 9.6% |
Fundamental Drivers
The -82.2% change in FEMY stock from 7/31/2025 to 8/23/2026 was primarily driven by a -64.8% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.58 | 2.96 | -82.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | 35.3% |
| P/S Multiple | 12.3 | 4.3 | -64.8% |
| Shares Outstanding (Mil) | 1 | 3 | -62.5% |
| Cumulative Contribution | -82.2% |
Market Drivers
7/31/2025 to 8/23/2026| Return | Correlation | |
|---|---|---|
| FEMY | -82.2% | |
| Market (SPY) | 22.2% | 13.7% |
| Sector (XLV) | 35.6% | 10.8% |
Fundamental Drivers
The -73.1% change in FEMY stock from 7/31/2023 to 8/23/2026 was primarily driven by a -82.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312023 | 8232026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.00 | 2.96 | -73.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 95.1% |
| P/S Multiple | 5.5 | 4.3 | -22.0% |
| Shares Outstanding (Mil) | 1 | 3 | -82.3% |
| Cumulative Contribution | -73.1% |
Market Drivers
7/31/2023 to 8/23/2026| Return | Correlation | |
|---|---|---|
| FEMY | -73.1% | |
| Market (SPY) | 73.2% | 2.9% |
| Sector (XLV) | 36.3% | 2.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FEMY Return | -68% | -77% | 8% | 13% | -48% | -76% | -99% |
| Peers Return | 31% | -30% | 2% | 2% | -24% | -40% | -57% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 12% | 103% |
Monthly Win Rates [3] | |||||||
| FEMY Win Rate | 29% | 17% | 33% | 25% | 42% | 25% | |
| Peers Win Rate | 50% | 35% | 46% | 56% | 50% | 34% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| FEMY Max Drawdown | - | -79% | -80% | -61% | -81% | -84% | |
| Peers Max Drawdown | -32% | -44% | -38% | -35% | -44% | -55% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: COO, BSX, MYGN, DARE.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/21/2026 (YTD)
How Low Can It Go
| Event | FEMY | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -21.1% | -7.8% |
| % Gain to Breakeven | 26.7% | 8.5% |
| Time to Breakeven | 5 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -16.1% | -9.5% |
| % Gain to Breakeven | 19.2% | 10.5% |
| Time to Breakeven | 5 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -60.8% | -6.7% |
| % Gain to Breakeven | 155.3% | 7.1% |
| Time to Breakeven | 78 days | 31 days |
In The Past
Femasys's stock fell -21.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 26.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | FEMY | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -21.1% | -7.8% |
| % Gain to Breakeven | 26.7% | 8.5% |
| Time to Breakeven | 5 days | 18 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -60.8% | -6.7% |
| % Gain to Breakeven | 155.3% | 7.1% |
| Time to Breakeven | 78 days | 31 days |
In The Past
Femasys's stock fell -21.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 26.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Femasys (FEMY)
Femasys Inc. (FEMY) is a biomedical company dedicated to advancing women's healthcare through the development and commercialization of innovative medical devices and non-surgical technologies. Based in Suwanee, Georgia, the company focuses on addressing critical needs within the women's health market, offering solutions ranging from permanent contraception to cancer detection and fertility support.
The company's product portfolio is diverse, featuring solutions for permanent birth control, specifically FemBloc and FemChec. In the fertility space, Femasys offers FemaSeed for artificial insemination. For diagnostics, it provides FemCerv, a biopsy device for endocervical curettage, and FemEMB, a product candidate designed for endometrial sampling to aid in uterine cancer detection. Additionally, Femasys commercializes the FemVue saline-air device, which is distributed across the United States, Europe, Canada, Japan, and other international markets.
Femasys primarily serves obstetrics-gynecological physicians (OB-GYNs), reproductive endocrinologists, and other related healthcare professionals and women's healthcare provider organizations. While its product development is largely focused on the United States market, its commercialized FemVue device extends its market reach globally to its target customers.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Femasys (FEMY):
- Hologic for non-surgical women's health technology.
- Exact Sciences for women's reproductive health diagnostics and devices.
AI Analysis | Feedback
- FemBloc: A permanent birth control solution.
- FemChec: A permanent birth control solution.
- FemaSeed: An artificial insemination solution.
- FemCerv: A biopsy device used for endocervical curettage.
- FemEMB: A product candidate for endometrial sampling to aid in uterine cancer detection.
- FemVue: A saline-air device commercialized internationally.
AI Analysis | Feedback
Femasys (FEMY) sells primarily to professional entities and healthcare organizations rather than directly to individual consumers. Based on the provided description, its major customers fall into the following categories:
- Obstetrics-gynecological physicians (OB-GYNs)
- Related healthcare professionals (e.g., those working in women's health clinics)
- Women's healthcare provider organizations (e.g., clinics, hospitals specializing in women's health)
- Reproductive endocrinologists (specialists in infertility)
The company's products are designed for use by these medical professionals and organizations to provide care and solutions to their patients.
AI Analysis | Feedback
AI Analysis | Feedback
Kathy Lee-Sepsick, President and Chief Executive Officer
Kathy Lee-Sepsick is the founder of Femasys, established in February 2004. She has nearly three decades of experience as a senior executive in the medical technologies industry, with a successful track record in growing emerging companies and corporate operating divisions. She held strategic and operational roles at start-ups Novoste Corporation, a developer of intravascular therapy solutions, and SaluMedica, a biomaterial developer. Earlier in her career, she managed product strategy at Terumo Medical Corporation, where she collaborated with Boston Scientific Corporation. She holds over 200 global patents for Femasys' products and product candidates.
Dov Elefant, Chief Financial Officer
Dov Elefant serves as the Chief Financial Officer for Femasys.
Daniel Currie, Chief Operating Officer
Daniel Currie was appointed Chief Operating Officer in August 2023, having previously served as Senior Vice President, Operations since 2009, and Vice President, Operations since 2004. He has over 30 years of operational experience in the medical device industry, including assignments at early-stage and large established companies such as Novoste Corporation and CIBA Vision Corporation. Mr. Currie is set to retire in December 2025.
Kelley Nicholas, Chief Commercial Officer
Kelley Nicholas was appointed Chief Commercial Officer in June 2025. She brings over 25 years of industry experience, including two decades leading high-performing commercial teams. Prior to joining Femasys, Ms. Nicholas was Head of Sales at NeuroPace and Global Vice President of Marketing at Hologic. Her leadership experience also includes global healthcare companies such as Medtronic, Baxter, Intuitive Surgical, and Covidien.
James H. Liu, M.D., Chief Medical Officer
Dr. James H. Liu was appointed Chief Medical Officer in November 2023. He previously served for over 21 years as Chairman, Department of Obstetrics and Gynecology at University Hospital Health System, and Chair, Department of Reproductive Biology at Case Western Reserve University. He also held the position of Division Head, Reproductive Endocrinology and Infertility at the University of Cincinnati. Dr. Liu has several issued patents and has served on the FDA Advisory Committee.
AI Analysis | Feedback
Key Risks to Femasys (FEMY)
- Regulatory and Clinical Trial Risk: The success of Femasys, particularly its lead product candidate, FemBloc (a non-surgical permanent birth control option), is highly dependent on successful completion of pivotal clinical trials and obtaining U.S. Food and Drug Administration (FDA) approval. Any significant delays or the emergence of safety issues during the ongoing FINALE pivotal clinical trial could severely impact the company's viability and stock performance. While FemBloc has received approvals in Europe, the UK, and New Zealand, U.S. regulatory clearance is crucial for broad commercialization.
- Financial Health and Funding: Femasys is currently in a heavy investment phase and is not profitable, reporting significant operating and net losses and a substantial accumulated deficit. The company faces a rapid cash burn rate and maintains a weak overall financial health score. While recent financing has been secured, the ongoing need for capital to fund product development, clinical trials, and commercialization efforts, coupled with potential shareholder dilution, presents a significant risk to its operations.
- Market and Competition Risk: Femasys operates within the women's health market, which features established and well-resourced competitors. The company faces challenges in differentiating its products and gaining widespread market adoption among obstetrics-gynecological physicians and other healthcare professionals. The commercial ramp-up for its core products has been slower than analyst predictions, and effective sales force activity is crucial for achieving market share against major players in segments like fertility.
AI Analysis | Feedback
AI Analysis | Feedback
Femasys Inc. operates in several women's healthcare markets, with its key products addressing significant needs globally and in the United States.
For its permanent birth control solutions, FemBloc and FemChec, the addressable market can be estimated within the broader permanent contraception and non-hormonal contraceptives sectors. The global transcervical female sterilization market was valued at approximately USD 808.94 million in 2026 and is projected to reach USD 1176.08 million by 2035. More broadly, the global female sterilization devices market was valued at USD 6.30 billion in 2024 and is expected to grow to USD 9.71 billion by 2032. In the U.S., female sterilization is the most common contraceptive method, utilized by 11.5% of the reproductive-age population. The U.S. sterilization services market was valued significantly in 2024.
FemaSeed, Femasys's artificial insemination solution, targets the artificial insemination and assisted reproductive technology (ART) markets. The global artificial insemination market was valued at USD 3.10 billion in 2025 and is predicted to increase to approximately USD 4.81 billion by 2035. Another estimate for the global artificial insemination market size was USD 2.26 billion in 2023, with a projected CAGR of 8.6% from 2024 to 2030. The U.S. artificial insemination market was valued at approximately USD 2.4 billion in 2024 and is projected to reach USD 3.8 billion by 2030. The larger global assisted reproductive technology (ART) market, which encompasses artificial insemination, was valued at USD 34.71 billion in 2025 and is anticipated to reach around USD 87.27 billion by 2035.
The FemCerv biopsy device for endocervical curettage falls within the gynecological devices and cervical cancer diagnostics markets. The global gynecological devices market was valued at USD 10.52 billion in 2024 and is projected to grow to around USD 23.22 billion by 2034. Surgical devices, a segment within gynecological devices, contributed 53% of the market share in 2024. For cervical cancer diagnostics, the global market size was valued at USD 4.4 billion in 2023 and is projected to reach USD 6.3 billion by 2030.
FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection, addresses the uterine cancer diagnostics market. The global uterine cancer diagnostics market size was valued at USD 10.53 billion in 2024 and is expected to reach USD 23.75 billion by 2032. The endometrial cancer segment constituted 81.7% of this market in 2024. The global uterine cancer diagnostic testing market is estimated at US$ 3.23 billion in 2024 and is forecasted to climb to a value of US$ 6.76 billion by the end of 2034. The North America uterine cancer diagnostics and treatment market was estimated to reach US$9.18 billion in 2024.
The FemVue saline-air device is utilized in hysterosalpingography (HSG) procedures. The global hysterosalpingography (HSG) market size was valued at US$ 2.02 billion in 2021 and is expected to reach nearly US$ 2.74 billion by 2029. Additionally, hysteroscopes, which are used to visualize the uterine cavity, are part of the global hysteroscope market, valued at USD 270.62 million in 2025 and projected to grow to USD 440.75 million by 2034.
AI Analysis | Feedback
Femasys (FEMY) is anticipated to drive future revenue growth over the next two to three years through several key initiatives:
- International Commercialization of FemBloc: The company expects significant revenue growth from the commercialization of FemBloc, its non-surgical permanent birth control solution, in international markets. FemBloc received full regulatory approvals in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Initial orders have already been placed by distribution partners in countries like Spain and France. This is considered a "new, high-growth driver" for Femasys.
- Potential U.S. Market Entry for FemBloc: Femasys has initiated patient enrollment in the FDA-authorized FINALE pivotal trial for FemBloc in the United States. Successful completion of this trial is expected to lead to a future U.S. regulatory submission, opening up a substantial new market for the product.
- Increased Sales and Market Penetration of FemaSeed: The FemaSeed intratubal insemination device has demonstrated strong growth in the U.S. market, with a 78% increase in sales during Q1 2025. The company is actively expanding its distribution reach through strategic partnerships, such as with CNY Fertility in the U.S. and Refuah Health Center. Additionally, FemaSeed received AMA CPT Editorial Panel approval for a new Category III CPT code in February 2026, which is expected to support its commercialization.
- Expansion of European Market for FemaSeed and Other Portfolio Products: Femasys is strategically expanding its commercial presence in Europe beyond FemBloc. This includes strengthening distribution partnerships for FemaSeed and other products within its portfolio, evidenced by a new partnership with a Swiss partner in February 2026.
- New Regulatory Clearances and Upgrades for Diagnostic Devices: Continued development and regulatory clearances for its diagnostic portfolio are expected to contribute to revenue. For instance, Femasys secured U.S. FDA clearance for its next-generation FemVue diagnostic device in December 2025, and its FemCath Intrauterine Catheter received product approval in Canada in June 2025. These advancements enhance the company's offerings and market access.
AI Analysis | Feedback
Share Issuance
- In May 2025, Femasys priced an underwritten public offering of 3,600,000 shares of common stock at $0.85 per share, and a concurrent private placement of 1,686,275 shares at $0.85 per share (to institutional stockholders) and $1.02 per share (to directors/officers), generating approximately $4.5 million in gross proceeds.
- In August 2025, Femasys announced the pricing of an underwritten public offering that included 10,434,586 shares of common stock, pre-funded warrants, and accompanying common warrants, expected to raise approximately $8 million in gross proceeds.
- In November 2025, Femasys entered into a definitive agreement for the issuance of $12 million in senior secured convertible notes and warrants, with potential total funding of up to $58 million if all warrants are exercised.
Inbound Investments
- In November 2025, Femasys secured $12 million through senior secured convertible notes and warrants from institutional and accredited investors, with the potential to reach $58 million if all warrants are exercised.
- A concurrent private placement in May 2025 involved certain existing institutional stockholders and company directors and officers purchasing shares as part of a capital raise.
Capital Expenditures
- Capital expenditures were approximately -$491,959 over the last 12 months (prior to March 2026).
- For the second quarter of 2025, capital expenditures reflected an outflow of approximately $0.19 million.
- Femasys intends to use proceeds from recent public offerings and private placements to fund various initiatives, including capital expenditures, alongside commercial expansion and product development.
Peer Outperformance in Health Care Equipment
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 9.5% | 82.4% | 124.2% | CAH 394% · MCK 340% · COR 184% |
| Health Care Services | 20 | 20.6% | 46.6% | 7.5% | HIMS 337% · RDNT 157% · DGX 80% |
| Managed Health Care | 8 | 29.7% | -3.0% | 0.6% | OSCR 158% · HQY 63% · ELV 14% |
| Health Care Facilities | 24 | 7.9% | -0.8% | -16.4% | THC 286% · NHC 265% · ENSG 123% |
| Health Care Equipment ← | 51 | -4.5% | -4.5% | -17.6% | POCI 11300% · UFPT 373% · GKOS 260% |
| Health Care Supplies | 12 | 33.9% | -12.1% | -26.0% | LNTH 297% · HAE 78% · MMSI 29% |
| Pharmaceuticals | 63 | 4.5% | 4.1% | -38.2% | LQDA 2499% · INDV 1253% · ETON 1190% |
| Health Care Technology | 21 | -19.9% | -53.0% | -72.5% | SPOK 115% · HSTM -1% · VEEV -23% |
| Life Sciences Tools & Services | 108 | -2.5% | -28.0% | -72.6% | SNWV 1782% · MEDP 245% · ELMD 225% |
| Biotechnology | 365 | 7.8% | -24.2% | -78.3% | BRTX 107550% · CELZ 1771% · DNTH 1543% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Femasys Earnings Notes | 12/16/2025 | |
| Femasys Stock Drop Looks Sharp, But How Deep Can It Go? | 10/17/2025 | |
| Day 5 of Gains Streak for Femasys Stock with 138% Return (vs. -24% YTD) [10/6/2025] | 10/07/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.20 |
| Mkt Cap | 0.3 |
| Rev LTM | 807 |
| Op Inc LTM | -11 |
| FCF LTM | -12 |
| FCF 3Y Avg | -12 |
| CFO LTM | 8 |
| CFO 3Y Avg | -11 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.5% |
| Rev Chg 3Y Avg | 11.7% |
| Rev Chg Q | 7.5% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 8.3% |
| Op Inc Chg 3Y Avg | 16.9% |
| Op Mgn LTM | -11.2% |
| Op Mgn 3Y Avg | 2.1% |
| QoQ Delta Op Mgn LTM | -3.5% |
| CFO/Rev LTM | 1.0% |
| CFO/Rev 3Y Avg | 7.2% |
| FCF/Rev LTM | -1.8% |
| FCF/Rev 3Y Avg | 0.1% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development and commercialization of therapeutic and diagnostic products that service women’s | 2 | 2 | 1 | 1 | 1 |
| Total | 2 | 2 | 1 | 1 | 1 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development and commercialization of therapeutic and diagnostic products that service women’s | -19 | -19 | -14 |
| Total | -19 | -19 | -14 |
Price Behavior
| Market Price | $2.96 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/18/2021 | |
| Distance from 52W High | -85.8% | |
| 50 Days | 200 Days | |
| DMA Price | $3.38 | $9.48 |
| DMA Trend | down | down |
| Distance from DMA | -12.3% | -68.8% |
| 3M | 1YR | |
| Volatility | 118.4% | 136.8% |
| Downside Capture | 466.33 | 230.05 |
| Upside Capture | -87.60 | 25.39 |
| Correlation (SPY) | 19.5% | 14.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.14 | 1.73 | 2.40 | 2.09 | 1.44 | 0.44 |
| Up Beta | 8.89 | 3.93 | 3.48 | 3.47 | 1.56 | 0.33 |
| Down Beta | 0.39 | 2.27 | 1.85 | 1.48 | 2.21 | 0.39 |
| Up Capture | -58% | -195% | -24% | 10% | -6% | 39% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 13 | 21 | 47 | 103 | 302 |
| Down Capture | 463% | 313% | 340% | 228% | 163% | 108% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 14 | 30 | 42 | 79 | 148 | 416 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FEMY | |
|---|---|---|---|---|
| FEMY | -76.3% | 136.6% | -0.44 | - |
| Sector ETF (XLV) | 28.8% | 16.0% | 1.39 | 11.6% |
| Equity (SPY) | 21.1% | 12.9% | 1.22 | 14.7% |
| Gold (GLD) | 37.5% | 28.8% | 1.10 | 15.4% |
| Commodities (DBC) | 43.2% | 20.2% | 1.66 | 0.7% |
| Real Estate (VNQ) | 12.9% | 13.8% | 0.64 | 3.1% |
| Bitcoin (BTCUSD) | -31.6% | 44.1% | -0.73 | 16.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FEMY | |
|---|---|---|---|---|
| FEMY | -54.5% | 204.6% | 0.16 | - |
| Sector ETF (XLV) | 7.1% | 15.1% | 0.28 | 3.4% |
| Equity (SPY) | 12.9% | 17.2% | 0.57 | 5.4% |
| Gold (GLD) | 20.6% | 18.6% | 0.90 | 1.7% |
| Commodities (DBC) | 10.4% | 19.6% | 0.41 | 2.5% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | 1.1% |
| Bitcoin (BTCUSD) | 10.4% | 52.8% | 0.38 | 7.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FEMY | |
|---|---|---|---|---|
| FEMY | -36.0% | 202.3% | 0.11 | - |
| Sector ETF (XLV) | 10.7% | 16.7% | 0.52 | 3.3% |
| Equity (SPY) | 15.2% | 17.9% | 0.72 | 5.3% |
| Gold (GLD) | 12.7% | 16.2% | 0.64 | 1.5% |
| Commodities (DBC) | 8.0% | 18.0% | 0.36 | 2.6% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.20 | 1.1% |
| Bitcoin (BTCUSD) | 63.1% | 66.1% | 1.03 | 7.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/24/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | -5.7% | 29.3% | |
| 5/8/2026 | -6.0% | -17.1% | -38.9% |
| 11/14/2025 | -11.3% | 2.5% | -14.6% |
| 8/8/2025 | -13.2% | -20.5% | -58.1% |
| 5/8/2025 | -7.8% | -7.0% | -30.4% |
| 11/12/2024 | -11.6% | -20.0% | 6.4% |
| 8/8/2024 | -18.1% | 1.0% | 1.9% |
| 5/9/2024 | -8.6% | -4.3% | -25.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 4 |
| # Negative | 14 | 12 | 12 |
| Median Positive | 2.8% | 6.8% | 3.0% |
| Median Negative | -8.4% | -9.1% | -26.1% |
| Max Positive | 6.0% | 29.3% | 6.4% |
| Max Negative | -18.1% | -20.5% | -58.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/14/2026 | -5.7% | 29.3% | |
| 5/8/2026 | -6.0% | -17.1% | -38.9% |
| 11/14/2025 | -11.3% | 2.5% | -14.6% |
| 8/8/2025 | -13.2% | -20.5% | -58.1% |
| 5/8/2025 | -7.8% | -7.0% | -30.4% |
| 11/12/2024 | -11.6% | -20.0% | 6.4% |
| 8/8/2024 | -18.1% | 1.0% | 1.9% |
| 5/9/2024 | -8.6% | -4.3% | -25.2% |
| 11/14/2023 | -10.6% | -8.7% | -27.0% |
| 8/10/2023 | -6.5% | -13.0% | -10.9% |
| 5/11/2023 | -13.1% | -7.9% | -20.7% |
| 11/10/2022 | 6.0% | 6.8% | -7.7% |
| 8/10/2022 | -8.1% | -3.8% | -8.6% |
| 5/11/2022 | 2.8% | 7.6% | 4.2% |
| 3/24/2022 | -3.9% | -2.2% | -30.7% |
| 11/10/2021 | 2.1% | -11.4% | -38.6% |
| 8/11/2021 | -2.7% | -9.5% | 1.8% |
| SUMMARY STATS | |||
| # Positive | 3 | 5 | 4 |
| # Negative | 14 | 12 | 12 |
| Median Positive | 2.8% | 6.8% | 3.0% |
| Median Negative | -8.4% | -9.1% | -26.1% |
| Max Positive | 6.0% | 29.3% | 6.4% |
| Max Negative | -18.1% | -20.5% | -58.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/14/2026 | 10-Q |
| 03/31/2026 | 05/08/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/27/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/24/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 06/21/2021 | 424B4 |
Insider Activity
Updated 8/11/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mifek, Jeffrey Gerald | Chief Clinical-Medical Affairs | Direct | Buy | 8112026 | 3.20 | 3,125 | 10,000 | 10,000 | Form |
| 2 | Sipos, Jeremy Alexander | Chief Technology Officer | Direct | Buy | 8112026 | 3.20 | 3,125 | 10,000 | 10,000 | Form |
| 3 | Canning, John Charles | Chief Operating Officer | Direct | Buy | 8112026 | 3.20 | 4,375 | 14,000 | 14,000 | Form |
| 4 | Elefant, Dov | Chief Financial Officer | Direct | Buy | 8112026 | 3.20 | 15,625 | 50,000 | 50,000 | Form |
| 5 | Lee-Sepsick, Kathy | Chief Executive Officer | Direct | Buy | 8112026 | 3.20 | 15,625 | 50,000 | 50,000 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mifek, Jeffrey Gerald | Chief Clinical-Medical Affairs | Direct | Buy | 8112026 | 3.20 | 3,125 | 10,000 | 10,000 | Form |
| 2 | Sipos, Jeremy Alexander | Chief Technology Officer | Direct | Buy | 8112026 | 3.20 | 3,125 | 10,000 | 10,000 | Form |
| 3 | Canning, John Charles | Chief Operating Officer | Direct | Buy | 8112026 | 3.20 | 4,375 | 14,000 | 14,000 | Form |
| 4 | Elefant, Dov | Chief Financial Officer | Direct | Buy | 8112026 | 3.20 | 15,625 | 50,000 | 50,000 | Form |
| 5 | Lee-Sepsick, Kathy | Chief Executive Officer | Direct | Buy | 8112026 | 3.20 | 15,625 | 50,000 | 50,000 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.